medullary thyroid cancer

ARIAD presents new preclinical data on ponatinib

ARIAD presents new preclinical data on ponatinib

The Fly on the Wall

JPMorgan Healthcare Conference Highlights: Exelixis

JPMorgan Healthcare Conference Highlights: Exelixis

Motley Fool

Exelixis' Crowning Achievement

Exelixis' Crowning Achievement

Motley Fool

Exelixis Wins First Approval of Cancer Drug

Exelixis Wins First Approval of Cancer Drug

Minyanville

Exelixis Traders Brace For Upcoming FDA Decision

Exelixis Traders Brace For Upcoming FDA Decision

Seeking Alpha

2 Important Decisions to Watch For This Week in the Biotech Sector

2 Important Decisions to Watch For This Week in the Biotech Sector

Motley Fool

Exelixis's Cabozantinib Should Receive FDA Approval, But Faces Long-Term Challenges

Exelixis's Cabozantinib Should Receive FDA Approval, But Faces Long-Term Challenges

Seeking Alpha

Exelixis Stock Treads Water Ahead Of FDA Decision

Exelixis Stock Treads Water Ahead Of FDA Decision

Seeking Alpha

Exelixis Provides Update on ODAC Panel for Cabozantinib

Exelixis Provides Update on ODAC Panel for Cabozantinib

Yahoo

FDA Grants Priority Review for Cabozantinib in Medullary Thyroid Cancer

FDA Grants Priority Review for Cabozantinib in Medullary Thyroid Cancer

Yahoo